Wednesday, May 18, 2011

Serono to pay $44.3 million for its marketing of Rebif

Pharmaceutical manufacturers Serono Laboratories, Inc., EMD Serono, Inc., Merck Serono S.A., and Ares Trading S.A., have agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif.  Click here for the story.  Click here for the DoJ press release.

No comments:

Post a Comment